logo-loader
viewNeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals taking a different approach to treat Alzheimer's Disease

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) Chief Scientific Officer Anton Uvarov sat down with Proactive at the 2019 BIO Investor Forum in San Francisco. 

The Australian-based biotech company is developing peptide therapeutics to treat neurodegenerative conditions.

Quick facts: NeuroScientific Biopharmaceuticals Ltd

Price: 0.235 AUD

ASX:NSB
Market: ASX
Market Cap: $13.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bull, Bears & Brokers: Shaw and Partner’s Davide Bosio on big moves in...

Shaw and Partners WA state manager Davide Bosio updates Proactive on big moves in metals markets this week, especially nickel and with indications that copper is also ready to move ahead. Bosio says that while gold is a measure of risk, uncertainty and fear, copper is a measure of growth and...

4 hours, 3 minutes ago

2 min read